摘要眼底新生血管性疾病是一类涉及视网膜和脉络膜血管异常增殖的眼科疾病。在其发病过程中血管内皮生长因子(VEGF)发挥着关键作用。抗VEGF药物(如哌加他尼、贝伐单抗、雷珠单抗、布西珠单抗、阿柏西普、康柏西普、法瑞西单抗等)可减轻血管渗漏、促进积液吸收以及加速新生血管消退等。眼底新生血管性疾病与多种因素有关，如可同时靶向治疗多个通道可能会产生更好的效果。随着新的给药方式、缓释药物以及靶向更多通路的新型药物的研发，抗VEGF药物为治疗眼底新生血管性疾病提供了更为高效、安全的选择。创新药物包括基因治疗药物ADVM－022、RGX－314，局部滴眼液有帕唑帕尼(pazopanib)、角鲨胺、瑞戈非尼(regorafenib)等，口服的酪氨酸激酶抑制剂CM082，以及雷珠单抗载药植入物均具有一定的前景。( 国际眼科纵览，2024, 48：464－470)

abstractsRetinal neovascularization is a type of ophthalmic disease that involves abnormal proliferation of retinal and choroidal blood vessels. Vascular endothelial growth factor (VEGF) plays a key role in the pathogenesis of fundus neovascular diseases. Anti-VEGF drugs (such as pegatinib, bevacizumab, ranibizumab, busizumab, aflibercept, conbercept, fariximab, etc) can reduce vascular leakage, promote the absorption of effusion and accelerate the regression of neovascularization. Neovascular diseases in the fundus are related to multiple factors, and targeting multiple channels simultaneously may produce better prognosis. With the development of new drug delivery methods, sustained-release drugs, and novel drugs targeting more pathways, anti VEGF drugs provide a more efficient and safe option for the treatment of retinal neovascularization. Innovative drugs include gene therapy drugs ADVM-022 and RGX-314, local eye drops such as pazopanib, squalylamine, regorafenib, oral tyrosine kinase inhibitor CM082, and monoclonal antibody drug loaded implants, all of which have certain prospects.( Int Rev Ophthalmol, 2024, 48: 464-470)